Boston Partners Invests $110.38 Million in Solventum Co. (NYSE:SOLV)

Boston Partners purchased a new stake in Solventum Co. (NYSE:SOLV - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,670,408 shares of the company's stock, valued at approximately $110,378,000. Boston Partners owned about 0.97% of Solventum as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in SOLV. Modus Advisors LLC acquired a new position in shares of Solventum during the fourth quarter worth approximately $25,000. Stonebridge Financial Group LLC acquired a new position in shares of Solventum during the fourth quarter worth approximately $26,000. Crews Bank & Trust acquired a new position in shares of Solventum during the fourth quarter worth approximately $32,000. True Wealth Design LLC lifted its position in shares of Solventum by 23,550.0% during the third quarter. True Wealth Design LLC now owns 473 shares of the company's stock worth $33,000 after purchasing an additional 471 shares in the last quarter. Finally, Prospera Private Wealth LLC acquired a new position in shares of Solventum during the third quarter worth approximately $35,000.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Morgan Stanley increased their price objective on shares of Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th. Wells Fargo & Company increased their price objective on shares of Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a report on Friday, February 28th. Piper Sandler increased their price objective on shares of Solventum from $75.00 to $84.00 and gave the company a "neutral" rating in a report on Friday, February 28th. Mizuho increased their price objective on shares of Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a report on Monday, March 3rd. Finally, Bank of America increased their price objective on shares of Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, Solventum presently has an average rating of "Hold" and an average price target of $79.86.

Remove Ads

Solventum Stock Performance

Shares of SOLV traded down $0.99 during midday trading on Friday, reaching $74.00. The stock had a trading volume of 1,919,810 shares, compared to its average volume of 1,429,530. The firm has a 50 day simple moving average of $75.17 and a 200-day simple moving average of $71.56. Solventum Co. has a one year low of $47.16 and a one year high of $85.92. The firm has a market cap of $12.80 billion and a PE ratio of 26.91. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.